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Abstract. It is estimated that >10,000 patients who undergo
cystectomy for bladder cancer in the US each year receive a
conventional ileal conduit and that >2,000 receive a continent
urinary diversion. Case reports of primary intestinal adenocarcinomas in urinary conduits have been published recently,
mainly in the urology literature. An epidemic of such cancers
in this small, high-risk population seems to be emerging,
particularly in conduits that utilize the colon. A case report and
literature review was carried out. We describe a patient with a
new primary adenocarcinoma arising in a colonic neobladder.
We summarize prior literature describing intestinal adenocarcinomas that developed in an intestinal segment used for
urinary diversion. Patients with urinary conduits of all types
(particularly those utilizing colon rather than ileum) are at high
risk of developing a second primary intestinal adenocarcinoma
in the conduit. This population is likely to benefit from surveillance measures aimed at detecting such cancers. The primary
form of therapy remains adequate surgical resection. General
surgeons should be aware of such patients as they may be
involved in the diagnosis of, and surgery for, the cancer in the
conduit.
Introduction
In 2008, the World Health Organization projected that cancer
would become the leading cause of death in the world (1).
Carcinoma of the urinary bladder is the ninth most commonly
diagnosed type of cancer in the world (2). Over 70,000 people
in the US develop this cancer every year (3) and the incidence
is projected to increase (4). Comparable data are reported from
other wealthy nations (5). In the US and most other countries,
tobacco abuse is the main known environmental risk factor
for the development of bladder cancer (6-8). The incidence in
smokers is estimated to be two to three times as great as the
incidence in non-smokers. In countries where S. haematobium
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is endemic, bladder infestation is the leading cause (2). In river
basins draining the Himalayas (e.g., India, Pakistan, Myanmar,
Vietnam), the groundwater contains high concentrations of
arsenic, which is a major cause of bladder carcinoma (9).
Additional known etiologic agents include exposure to certain
aromatic amines such as those found in dyes and rubber, the
chemotherapeutic agent cyclophosphamide, ionizing radiation,
and various textiles and metals (7,10,11).
Colorectal carcinoma is the third most commonly diagnosed
type of cancer in the world (1). Over 150,000 people in the US
develop cancer of the colon or rectum every year (12). Adenomas
arising in subjects without known polyposis syndromes are the
most common precursor lesion. Hamartomas are also welldescribed precursor lesions, as in Peutz-Jehgers syndrome. Other
known causes of colorectal cancer include hereditary polyposis
syndromes, Li-Fraumeni syndrome, inflammatory bowel
disease, and ionizing radiation (13,14). Charred food and diets
high in red meat and low in fiber, fruits and vegetables have been
implicated as causative environmental agents (15-17). There is
some evidence that a human colonic bacterium promotes colonic
tumorigenesis (18). Tobacco abuse, including secondhand smoke
exposure, is also associated with colorectal carcinoma development (19), and the relationship appears to be dose-dependent (20).
Over 6,000 new cases of small intestinal cancer are diagnosed
in the US annually (12). These include carcinoid, adenocarcinoma, lymphoma, and sarcoma/gastrointestinal stromal tumor.
Cancer of the small intestine accounts for about 1-2% of all
gastrointestinal cancers. Predisposing causes include familial
polyposis syndromes, Peutz-Jehgers syndrome, Crohn's disease,
hereditary non-polyposis colon cancer syndromes, and cystic
fibrosis (21). Because of the rarity of these cancers, the role of
environmental agents such as tobacco-derived carcinogens has
not been fully explored (22).
About 75% of bladder cancers are low-grade and nonmuscle-invasive. They are usually managed by cystoscopic
resection. Radical cystectomy is the mainstay of treatment
for muscle-invasive carcinoma (though partial cystectomy is
occasionally utilized). After radical cystectomy, some form of
urinary diversion is required. Direct implantation of the ureters
into non-isolated intestinal segments, particularly colon, was
employed quite frequently after it was first described in 1852
by Simon (23). Feris and Odel reported that patients with a
uretero-sigmoidostomy often had intractable hyperchloremic
metabolic acidosis and other metabolic complications so this
procedure is now used infrequently (23). Uterosigmoidostomy
was also found to lead to adenocarcinoma of the colon adjacent
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Figure 1. Photograph of the fresh specimen. The wooden pointer indicates the carcinoma (1 cm in diameter). It is adjacent to the lumen of the appendix (white
arrow). There is a linear mucosal erosion (black arrow) caused by the blue ureteral stent.

to the location of ureteral implantation in an animal model (24).
Austen and Kälble estimated that individuals between the ages
of 25 and 30 with this form of diversion have a 477-fold increased
lifetime risk of colon carcinoma and that patients between the
ages of 55 and 60 years have an 8-fold increased lifetime risk
(25).
Currently, urinary diversion into isolated bowel, typically
ileum, is the most common method used after cystectomy
(23,26). It was introduced by Bricker in the mid-twentieth
century (27). Tizzoni and Foggi were the first to attempt creation
of a neobladder in 1888 but the results were not satisfactory (23).
During the 1970s, continent pouches were introduced again.
In this procedure, a segment of bowel is isolated on a vascular
pedicle, detubularized and reconfigured to create a spherical,
low-pressure conduit. Ureters are implanted and the pouch is
either connected to the native urethra (orthotopic neobladder)
or a catheterizable stoma is created. Today, in young patients
without major comorbid conditions, the orthotopic neobladder
is the most commonly utilized form of urinary diversion and
allows for a good quality of life (28,29).
The pattern of carcinogenesis in patients with urinary diversions that maintain separation of urine and feces is different than
that of patients with ureterosigmoidostomies. Cancers occurring
after uterosigmoidostomy are almost all colon adenocarcinomas;
those in isolated intestinal segments used for urinary diversion
are usually adenocarcinomas but sarcomas and transitional
cell, squamous cell, and oat cell carcinomas also occur occasionally. The location of cancer developing in patients with
ureterosigmoidostomy in practically always at the ureteroenteric
anastomotic sites; those arising in isolated intestinal segments
used for urinary diversion are located at the ureteroenteric anastomotic sites in ~58% of instances and elsewhere in the conduit
in the remaining 42% (25).
Despite the risk of metabolic and other complications, the
use of intestinal segments for urinary diversion is generally pref-

erable to other options (cutaneous ureterostomy, percutaneous
nephrostomy, or tissue-engineered bladder) (29). However, it is
now also clear that patients with ileal conduits and continent
diversions of various types (e.g., continent conduits and orthotopic neobladders) are at risk for second primary cancers. About
13,000 individuals receive a cystectomy for bladder carcinoma in
the US each year, and~17% undergo continent diversion (28,29).
Based on these statistics, we estimate that about 11,000 patients
receive an ileal conduit and >2,000 receive a neobladder each
year in the US. In the US, the colon is used for the neobladder
in about half of those who receive continent diversion; the
small intestine is used for the other half. Considering that the
neobladder procedure has been regularly used for the past
twenty years, perhaps 10,000 people in the US currently have
a neobladder. The typical latency period for developing cancer
in an intestinal segment used for urinary diversion is about two
decades. Because the mean survival duration for patients who
have received curative-intent treatment for bladder carcinoma
continues to increase, the risk of developing cancer in a urinary
conduit for each patient is also increasing. It seems likely that
an epidemic of such cancers, particularly in those who continue
to smoke, is emerging at present. We sought to alert general
surgeons about this phenomenon as they are likely to be asked
to provide surgical care for such patients more frequently in the
future.
Materials and methods
We recently encountered a patient who developed a new primary
adenocarcinoma in an orthotopic neobladder created at the
time of radical cystectomy for transitional cell carcinoma of the
bladder 22 years earlier. Two separate literature searches were
performed using PubMed on January 17, 2010. To evaluate the
prior literature on this topic, one search mimicked that used by
Austen et al (25). The search criteria were ‘urinary diversion’ and
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Figure 2. Conventional ileal diversion. A segment of the intestine directs
urine through a stoma into an external collecting bag. Cleveland Clinic:
Treatment and Procedures. Urinary Reconstruction and Diversion. http://
my.clevelandclinic.org/services/urinary_reconstruction_and_diversion/hic_
urinary_reconstruction_and_diversion.aspx

Figure 3. Neobladder. Intestine is made into a reservoir and connected to the
urethra. Cleveland Clinic: Treatment and Procedures. Urinary Reconstruction
and Diversion. http://my.clevelandclinic.org/services/urinary_reconstruction_
and_diversion/hic_urinary_reconstruction_and_diversion.aspx

‘carcinoma’, using ‘case reports’ as a limitation. All languages
were accepted. The second literature search, also using PubMed,
was identical in all respects except that the search criteria were
‘neobladder’ and ‘carcinoma’ with ‘case reports’ as a limitation.

There were 550 reports retrieved with our first computergenerated literature search. Sixty-six described cases of tumor
development in patients with isolated intestinal urinary diversions created after cystectomy for bladder cancer (Fig. 2). There
were 77 reports retrieved with the second search; 15 described
cancers that developed in orthotopic neobladders (Fig. 3). Most
were adenocarcinomas but transitional cell carcinoma, squamous cell carcinoma, small cell undifferentiated carcinoma, and
mesenchymal cancers such as lymphomas and sarcomas were
also reported.

Results
Case report. In 1987, a 48-year-old male was diagnosed with
muscle-invasive transitional cell carcinoma of the urinary
bladder. He had smoked 1.5 packs of cigarettes per day for
many years. He underwent a cystoprostatectomy and had
an ileocolonic neobladder constructed to provide continent
urinary diversion. He continued to smoke cigarettes and in 2008
he presented with symptomatic gallstone disease. Urology
consultation was requested prior to cholecystectomy in order
to determine whether further urologic procedures (revision of
the neobladder, treatment of new primary urothelial tumors,
etc.) might be indicated at the same operation. New-onset
microscopic hematuria was detected and cystoscopy revealed
two papillary tumors in the neobladder. One was invasive
adenocarcinoma. Colonoscopy revealed no lesions in the
colon remaining after the neobladder creation. He underwent
open cholecystectomy, radical resection of the neobladder with
regional lymphadenectomy, and implantation of ureters into a
standard ileal conduit (Fig. 1). The operation was carried out
by both surgeons and urologists. The prior radical cystectomy
posed significant technical difficulties. Stents proved to be
useful in avoiding damage to the ureters. Particular care was
required to avoid injury to the obturator nerves, pelvic vessels,
and the like, as much of the tissue overlying these structures
had been resected at the time of the cystectomy. The pathology
report indicated T1N0M0 colon adenocarcinoma. The second
lesion seen at cystoscopy was an adenoma. The patient had no
evidence of recurrence two years later.

Discussion
It has been known for several decades that aromatic amine
exposure in an occupational setting and tobacco abuse account
for the majority of cases of bladder cancer in most areas of
the world (30). As the exposure to carcinogens arising from
industrial sources has been decreasing in the US, the proportion of bladder cancers caused by tobacco abuse is increasing
(31). Most experts conclude that the risk of cancer in isolated
bowel segments used for urinary diversion after cystectomy is
directly and causally related to the tobacco-derived urinary
carcinogens bathing the epithelium, since most patients who
abused tobacco before developing bladder carcinoma continue
to smoke after cystectomy.
Since ureterosigmoidostomy is such a reliable model of
colonic carcinogenesis, potential mechanisms have been investigated. One mechanism which could simultaneously explain
tumor occurrence in both isolated and non-isolated gut segment
urinary diversions involves inflammatory mediators (32). There
are numerous reports implicating epidermal growth factor,
various transforming growth factors and cytokines, and cyclooxygenase-2 in the process of carcinogenesis, particularly in
chronically inflamed tissues such as these urinary conduits (25).
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The causative role of tobacco abuse in carcinogenesis
has been reviewed by Hecht (33). There are dozens of known
carcinogens in cigarette smoke (34). They comprise various
classes of agents and many are excreted in urine (35). Those
agents believed to be most responsible for bladder carcinoma
are 4-aminobiphenyl and other aromatic amines, although their
relative potencies on a molar basis are not known. Whether
tobacco-derived carcinogens are responsible for carcinoma of
the small intestine is unknown at present since research on this
topic is minimal (22). Hannan et al have provided a quantitative
estimate of the risk of colorectal cancer in smokers (36). The
relative importance of the various tobacco-derived carcinogens
in carcinogenesis of the colon and rectum is uncertain. Many
other ingested carcinogens derived from dietary sources are
present in the colon. Resident bacterial, fungal, viral, and
eukaryotic intestinal organisms, including protozoans (such
as amoebas) and metazoans (such as tapeworms) produce an
enormous number of metabolic products, most of which are not
characterized. The causal relation between cigarette smoking
and colorectal carcinogenesis has been well established recently
(19,20). Tobacco-derived nitrosamines and heterocyclic amines
are likely causative agents (33-39). The carcinogens responsible
for carcinomas arising in intestinal segments used for urinary
conduits are unknown but renal metabolism and urinary excretion of tobacco-derived chemicals is an important route of
elimination of these substances. Because 4-aminobiphenyl and
other small aromatic amines are present in urine and appear
to be the dominant known chemicals responsible for bladder
cancer in tobacco abusers, they may be presumed to cause
cancer in intestinal urinary conduits as well.
According to the Centers for Disease Control and Prevention,
approximately 45 million Americans smoke cigarettes and are
unable to quit (40). A person who continues to smoke after
resection of his/her bladder cancer is at risk of developing a
primary adenocarcinoma in the diverted bowel segment. The
long-term exposure of bowel mucosa to tobacco-derived and
non-tobacco-derived fecal carcinogens prior to the cystectomy,
followed by exposure to urine containing different carcinogens
derived from cigarette smoke, in addition to the proinflammatory environment of the conduit, appears sufficient to explain
the development of adenocarcinoma in patients with an orthotopic neobladder such as the patient described herein.
The risk of intestinal adenocarcinoma in a urinary conduit
in patients with spina bifida or bladder exstrophy who receive a
urinary diversion is appreciable (41). These patients presumably
warrant periodic surveillance for this event, like patients after
cystectomy for bladder carcinoma. The absolute risk of intestinal
adenocarcinoma in a urinary conduit following cystectomy for
bladder carcinoma is not known at present although there are
many more such patients than spina bifida or bladder exstrophy
patients. Sakano et al were apparently the first to report a patient
who developed adenocarcinoma in an ileal conduit after cystectomy for bladder carcinoma (42). Albertini et al were apparently
the first to describe an adenocarcinoma arising in the colonic
mucosa of a continent urinary reservoir following cystectomy
for bladder cancer (43). Reports have usually been in the urology
literature and occasionally in gynecology (44) and general
surgery (45) studies. The literature prior to 2004 has been
summarized by Austen and Kälbe (25). Our literature search
yielded four case reports of intestinal adenocarcinoma arising in

a urinary conduit created from an isolated segment of intestine
since 2004 (46-49). It seems likely that the overall incidence of
such second cancers is increasing.
In conclusion, as the results of treatment for bladder cancer
are steadily improving, long-term survivors may develop other
disorders requiring abdominal surgery, as in the case reported
here. A general surgeon contemplating an elective abdominal
operation for any reason in a patient who has had a prior cystectomy for bladder carcinoma should be alert to the potential need
for an additional procedure involving the urinary system. We
believe that urological consultation and appropriate diagnostic
tests should be obtained. Purely urological disorders (ureterenteric stricture, stones, etc.) may be discovered and warrant
treatment at the same time. If an intestinal adenocarcinoma
is found in the urinary conduit, resection may be curative.
Collaboration between the general surgeon and the urologist can
yield good results, as we have demonstrated.
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